A Case Study : Patients And Control Group

Mrs. Warley’s perspective of her situation is pessimistic, she feels that her outlook is bleak. As supported by Apar et al (2007), these fears are warranted as prognosis for SLCL is poor, with the median survival after treatment being approximately 15 months, and one in four patients surviving 2 years. In contrast, Mrs. Warley’s partner maintains a positive outlook and believes that

1. A 54-year-old patient is seen by the physician in the outpatient clinic setting for CLL that is currently in remission. The patient's WBC counts, particularly lymphocytes remain within normal limits

The prognosis of this disease tend to have a shorter life span but careful management of the symptoms and complications that could be improved of the daily life and increase the life span.

To calculate the number of CVC days, the number of patients with CVC will be counted every day consistently between 12.00 am and 01.00 am. The number of days will be summed at the end of every quarter. Only one line day will be calculated per patient day even if the patient had multiple CVC placed on the same day. The number of CLABSIs both in the control and the intervention group will be document daily in a tally sheet and summed every quarter. The CLABSI rate per 1000 central line days will then be calculated by dividing the number of CLABSIs by the number of central line days and multiplying the result by 1000. (CLABSI 푅푎푡푒푠 = {# CLABSI 퐼푑푒푛푡푖푓푖푒푑 ÷ # 표푓 CVC 퐷푎푦푠} 푥 1000) (Centers for Disease Control and Prevention {CDC}, 2017). The data will be collected at the ratio level of measurement. The parametric statistical analysis using the independent samples t-test will then compare the rate of CLABSIs in the intervention group and the control group to determine if there was a significant difference after implementing the CHG dressing’s

The table below will summarize the physiological aspects as well clinical manifestations shown in AML.

In our model, "death" could be because of CVD or different reasons. The overall age and gender

60% of lupus patients will develop clinically LN at some time in the course of their illness (Appel et al. 2007).

Chronic myelogenous leukemia is a disease where the bone marrow produces to many white blood cells. This disease is also called CML or chronic granulocytic leukemia. It is a slow progressing blood and bone marrow disease that most often occurs during or after middle age, and hardly ever occurs in children. Chronic myelogenous leukemia accounts for approximately 20% of all leukemia-affecting adults. The term “chronic” means this cancer tends to progress more slowly and last for a long period of time, “myelogenous” refers to the type of cells that are affected.

Unlike acute forms of leukemia, in which the cardinal manifestations (fever, weight loss, and fatigue) appear abruptly, patients with CML may be asymptomatic for months or even years prior to diagnosis. Even after diagnosis, many patients with chronic forms of leukemia survive 5-10 years or longer. In approximately 90% of CML patients an abnormal structure known as the Philadelphia chromosome results from an event known as a chromosomal translocation.

When determining your risk of non-Hodgkin’s lymphoma, the following are factors to be considered: Having HIV/AIDS, autoimmune conditions, Human T-lymphotrophic virus type I or Epstein-Barr virus infection, H pylori; taking immunosuppressant drugs post-organ transplant; and being an older white male. Also, there are an estimated of 72,240 new cases and 20,140 deaths (PDQ Adult Treatment Editorial Board, 2017).

Chronic leukemia is slow moving. Chronic leukemia has three types: Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), and Chronic Myelomonocytic Leukemia (CMML). Chronic Lymphocytic Leukemia is the most common in adults. CLL is when there is an over abundant amount of white blood cells in the bone marrow, which causes them to become abnormal and cause the body to not be able to fight off infections. Chronic Myeloid Leukemia is the same as CLL. It produces too many white blood cells. The only difference between the two is that CML has an abnormal chromosome as well. The last chronic type of leukemia is Chronic Myelomonocytic Leukemia when someone does not make enough blood. Some of their undeveloped cells do not ever become developed.

Low SES is an independent prognostic factor in receiving standard therapy. Retrospective population bases study in California showed that only 16.4% of low SES patients received standard therapy versus 36% of the highest SES.3

Acute Myeloid Leukemia (AML) is the most common form of leukemia in adults, approximately 20,800 people are diagnosed each year, leading to the lowest survival rate of all of the leukemias. It is a category of cancer of the blood and also the bone marrow (the soft inner part of some bones), and inside the spongy bone where blood cells are created. The average age for this type of leukemia is 65 or older, and is also generally more common in males rather than females. Acute Myeloid Leukemia is cured in 35-40% of people less than 60 years old and 5-15% in people older than 60 years old. If untreated, it can be fatal, and also it can spread to other parts of the body, including organs and tissues. Doctors still do not know what causes AML due to the fact that most people with this disease do not have risk factors that can be altered. Treatment of the AML always depends on the subtype of AML, and some treatments mays include high-dose

In conclusion, the risk of PML was stratified based on the anti-JC virus antibodies status, the previous use of immunosuppressant, and the length of natalizumab treatments. In addition, the patients that

disease. Nowadays, there are improvement of AML in 35 to 40% of adult patients who are ≤ 60